[144] RESMED INC SEC Filing

Rhea-AI Filing Summary

Form 144 notice for ResMed Inc. (RMD) reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services LLC on 10/07/2025 with an aggregate market value of $2,265,331.98. The filing identifies the securities as acquired under an option granted on 11/14/2018 and lists cash as the payment method.

The notice also discloses three prior sales by the same seller, each of 8,009 shares on 07/07/2025, 08/07/2025, and 09/08/2025 with gross proceeds shown for each transaction. The filer certifies they are not aware of undisclosed material adverse information and includes the standard signature/attestation language.

Positive

• Full disclosure of proposed sale including broker, share count, and aggregate market value
• Acquisition source identified (option granted on 11/14/2018)
• Three prior monthly sales disclosed showing consistent reporting of recent activity

Negative

• Repeated monthly sales of the same lot size (three months) which increase cumulative disposition visibility
• No plan adoption date listed in the Rule 10b5-1 field, leaving plan reliance unclear

Insights

Corporate Insider Trading Analyst

TL;DR: Repeated monthly sales of identical lot size are disclosed; filings show acquisition via option and cash sale planned on 10/07/2025.

The seller reports an option grant dated 11/14/2018 as the acquisition source and proposes to sell 8,009 shares with an aggregate market value of $2,265,331.98 on 10/07/2025 through Fidelity. The record includes three prior monthly sales of 8,009 shares each in 07/07/2025, 08/07/2025, and 09/08/2025.

Key dependencies are the timing and execution of the listed trades and conformance with Rule 144 aggregation rules; monitor actual trade settlement dates and any subsequent filings within the next 30 days.

Securities Compliance Specialist

TL;DR: The filing contains the required attestation and lists broker, share count, acquisition method, and recent sales history.

The notice names the broker, provides the number of shares outstanding (146,414,839) and shows gross proceeds from three recent sales. The signer affirms absence of undisclosed material adverse information and includes standard Rule 10b5-1 reference fields (blank where not applicable).

Compliance-wise, the filing appears to provide the mandatory disclosures; confirm whether any trading plan adoption date is present if relying on Rule 10b5-1 and watch for any follow-up Form 4 or amended Form 144 filings within normal reporting windows.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	8009	2265331.98	146414839	10/07/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/07/2025	Option Granted - 11/14/2018	Issuer			8009	10/07/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	07/07/2025	8009	2056076.09
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	08/07/2025	8009	2238378.55
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	09/08/2025	8009	2227590.42

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for ResMed (RMD) report?

The Form 144 reports a proposed sale of 8,009 common shares on 10/07/2025 via Fidelity Brokerage Services LLC with an aggregate market value of $2,265,331.98.

How were the shares being sold by the RMD filer acquired?

The securities were acquired under an option grant dated 11/14/2018, with the filing listing the acquisition date as 10/07/2025 and payment as cash.

Has the seller disclosed recent sales in the past three months?

Yes. The seller reported three prior sales of 8,009 shares each on 07/07/2025, 08/07/2025, and 09/08/2025 with gross proceeds listed for each.

What broker will execute the proposed RMD sale?

The filing names Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI) as the broker for the proposed transaction.

What outstanding share count does the Form 144 show for the issuer?

The Form 144 lists 146,414,839 shares outstanding for the issuer.